
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical is a clinical-stage oncology therapeutics company with a positive outlook due to its innovative Alpha DaRT technology, which has shown promising results in treating various types of solid tumors in clinical trials. Their recent partnerships, such as the one with Tolmar for developing and commercializing Alpha DaRT for prostate cancer in the US, demonstrate the potential for increased revenue and market expansion. Furthermore, the company has a strong financial position with a projected market value of $1.31 billion and promising clinical data, making it a favorable investment opportunity for long-term growth. However, risks to consider include potential failures in clinical trials and regulatory approvals, as well as competition in the market.
Bears say
Alpha Tau Medical is a clinical-stage oncology therapeutics company with a negative outlook due to its limited market size and potential competition, as well as potential risks related to the failure of Alpha DaRT in clinical trials and achieving commercial success. The company's valuation is derived from a DCF analysis-based asset value of $1.23B, with a discounted cash flow analysis that includes a 15% discount rate and 2% terminal growth rate. Risks also include potential dilution risk and failure to secure regulatory approval in the US.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares